Prognosis of T1G3 tumors: Clinical factors

European Urology, Supplements

Volumn 3, Issue 3, 2004, Pages 73-78

  Barmoshe, Sas ^a   Zlotta, Alexandre R ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; IMMUNOLOGIC AGENT;

BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CYSTOSCOPY; HUMAN; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 1542328906     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.02.013     Document Type: Conference Paper

References (74)

1. Herr H.W. Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br. J. Urol. 80:1997;762-765.
2. Eure G.R., Cundiff M.R., Schellhammer P.F. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J. Urol. 147:1992;376-379.
3. Lebret T., Gaudez F., Herve J.M., Barre P., Lugagne P.M., Botto H. Low-dose BCG instillation in the treatment of stage T1 grade 3 bladder tumors: recurrence, progression and success. Eur. Urol. 34:1998;67-72.
4. Loening S., Narayana A., Yoder L, et al. Analysis of bladder tumor recurrence in 178 patients. Urology. 16:1980;137-141.
5. Dalesio O., Schulman C.C., Sylvester R, et al. Prognostic factors in superficial bladder tumors. A study of the European Organisation for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J. Urol. 129:1983;730-733.
6. Shinka T., Matsumoto M., Ogura H, et al. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long term follow-up. Int. J. Urol. 4:1997;139-143.
7. Witjes J.A., Kiemeney L.A.L.M., Schaafsma H.E, et al. The influence of review pathology on the study outcome of a randomized multicenter superficial bladder cancer trial. Br. J. Urol. 73:1994;172-176.
8. Mulders P.F., van der Meijden A.P., Doesburg W.H, et al. Prognostic factors in pTa-pT1 superficial bladder tumors treated with intravesical instillations. The Dutch South-Eastern Cooperative Urological Group. Br. J. Urol. 73:1994;403-408.
9. Parmar M.K.B., Freedman L.S., Hargreave T.B, et al. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer. J. Urol. 142:1989;284-288.
10. Pansadaro V., Emiliozzi P., Defidio L, et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J. Urol. 154:1995;2054-2058.
11. Herr H.W., Badalament R.A., Amato D.A, et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol. 141:1989;22-28.
12. Kiemeney L.A.L.M., Witjes J.A., Heijbroeck R.P, et al. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-operative Urological Group. Br. J. Urol. 73:1994;164-171.
13. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 163:2000;73-78.
14. Holmäng S., Hedelin H., Anderstrom C., Holmberg E., Johansson S.L. The importance of the depth on invasion in stage T1 bladder carcinoma: a prospective cohort study. J. Urol. 157:1997;800-804.
15. Coplen D.E., Marcus M.D., Myers J.A, et al. Long term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free tumor. J. Urol. 144:1990;652-657.
16. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials. J. Urol. 168:2002;1964-1970.
17. Pawinski A., Sylvester R., Kurth K.H, et al. A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J. Urol. 156:1996;1934-1940.
18. Boccon-Gibod L., Leleu C., Herve J.M, et al. Bladder tumors invading the lamina propria (stage Ta-T1): Influence of endovésicale bacillus Calmette-Guerin therapy on recurrence and progression. Eur. Urol. 16(6):1989;401-404.
19. Younes M., Sussman J., True L.D. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 66:1990;543-548.
20. Smits G., Schaafsma E., Kiemeney I, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 52:1998;1009-1013.
21. Sozen S., Akbal C., Sokmensuer C. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). Urol. Int. 69:2002;200-206.
22. Holmäng S. Follow-up of patients with non-invasive and superficially invasive bladder cancer. Semin. Urol. Oncol. 18:2000;273-279.
23. Prout G.R. Jr., Griffin P.P., Daly J.J, et al. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer. 52:1983;524-532.
24. Vicente J., Laguna M.P., Duarte D, et al. Carcinoma in situ as a prognostic factor for G3, pT1 bladder tumors. Br. J. Urol. 68:1991;380-382.
25. Smits G., Schaafsma E., Kiemeney L., Caris C., Debruyne F., Witjes J.A. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 52:1998;1009-1014.
26. Solsona E., Iborra I., Dumont R, et al. The 3 month clinical response to Intravesical therapy as a predictive factor for progression in the patients with high risk superficial bladder cancer. J. Urol. 164:2000;685-689.
27. Kurth K.H., Denis L., Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur. J. Cancer. 31A:1995;1840.
28. Brausi M., Colette L., Kurth K., Van der Meijden A.P, et al. EORTC Genito-Urinary Tract Cancer Collaborative Group Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta/T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41(5):2002;523-531.
29. Witjes J.A., Kiemeney L.A.L.M., Oosterhof G.O.N, et al. Prognostic factors in superficial bladder cancer. A review. Eur. Urol. 21:1992;89-97.
30. Hara I., Miyake H., Takechi Y, et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int. J. Urol. 10:2003;19-24.
31. Holmang S., Johansson S.L. Stage Ta-T1 bladder cancer: the relationship between findings at the first follow-up cystoscopy and subsequent recurrence and progression. J. Urol. 167:2002;1634-1637.
32. Pham H.T., Soloway M.S. High-risk superficial bladder cancer: intravesical therapy for T1, G3 transitional cell carcinoma of the urinary bladder. Semin. Urol. Oncol. 15:1997;147-153.
33. Jakse G., Loidl W., Seeber G, et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol. 137:1987;39-43.
34. Patard J.J., Moudouni S., Saint F., Rioux-Leclerq N., Manunta A., Guy L, et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology. 58:2001;551-556.
35. Lamm D.L., Blumenstein B.A., Crawford E.D, et al. A randomized trial of Intravesical doxorubicin and immunotherapy with bacilli Calmette-Guerin for transitionl cell carcinoma of the bladder. New. Engl. J. Med. 325:1991;1205-1209.
36. Huben R.P. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. Semin. Urol. Oncol. 14(1 Suppl 1):1996;17-22.
37. Bono A.V., Lovisolo J.A., Saredi G. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Eur. Urol. 37:2000;478-483.
38. Bilen C.Y., Ozen H., Aki F.T, et al. Clinical experience with BCG alone versus BCG plus epirubicin. Int. J. Urol. 7:2000;206-209.
39. Malmström P.U., Wijkström H., Lundholm C, et al. 5 year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J. Urol. 161:1999;1124-1127.
40. Malmström P.U. Improved patient outcomes with BCG immunotherapy vs. chemotherapy: Swedish and worldwide experience. Eur. Urol. 37(Suppl 1):2000;16-20.
41. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J. Urol. 148:1992;797-801.
42. Krege S., Giani G., Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only vs. transurethral resection plus mitomycin C vs. transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J. Urol. 156:1996;962-966.
43. Smith J.A. Jr., Labasky R.F., Cockett A.T, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stage Ta, T1 and Tis). American Urological Association. J. Urol. 162:1999;1697-1701.
44. Herr H.W. Uncertainty and outcome of invasive bladder tumors. Urol. Oncol. 2:1996;92-95.
45. Otto T., Rubben H. Management of T1G3 bladder tumors. Eur. Urol. Update Ser. 3:1994;122-125.
46. Abel P.D., Henderson D., Bennett M.K., Hall R.R., Williams G. Differing interpretations by pathologists of the pT category and grade of transitional cell carcinoma cancer of the bladder. Br. J. Urol. 62:1988;339-342.
47. Angulo J.C., Lopez J.I., Grignon D.J., Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology. 45:1995;47-53.
48. Bol M.G., Baak J.P., Buhr-wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J. Urol. 169:2003;1291-1294.
49. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 162:1999;74-76.
50. Pieras E., Palou J., Salvador J, et al. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur. Urol. 44:2003;222-225.
51. Stockle M., Alken P., Engelmann G., Jacobi H., Riedmiller H., Hohenfellner R. Radical cystectomy- often too late? Eur. Urol. 13:1987;361-367.
52. Amling C.L., Thrasher J.B., Frazier H.A., Dodge R.K., Robertson J.E., Paulson D.F. Radical cystectomy for stages Ta, T1 and Tis transitional cell carcinoma of the bladder. J. Urol. 151:1994;31-36.
53. Freeman JA, Esrig D, Simoneau A et al, Radical cystectomy for patients with superficial bladder cancer. J Urol 1994; 151(Suppl.):Abstract 25.
54. Catalona W.J., Hudson M.A., Gillen D.P, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol. 137:1987;220-224.
55. Baniel J., Grauss D., Engelstein D, et al. Intravesical bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urolgy. 52:1998;785-789.
56. Kavoussi L.R., Torrence R.J., Gillen D.P, et al. Results of 6 weekly intravesical bacillus Calmette-Guerrin instillations on the treatment of superficial bladder tumors. J. Urol. 139:1988;935-938.
57. Zlotta A.R., Schulman C.C. Biological markers in superficial bladder tumors and their prognostic significance. Urol. Clin. North Am. 27:2000;179-189.
58. Heney N.M., Ahmed S., Flanigan M.J, et al. Superficial bladder cancer: progression and recurrence. J. Urol. 130:1983;1083-1086.
59. Zungri E., Martinez L., Da Silva E.A, et al. T1G3 bladder cancer. Management with tranurethral resection only. Eur. Urol. 36:1999;380-384.
60. Klan R., Hardung R., Meier T, et al. Progression in T1G3 urothelial bladder cancer: impact of therapy (Abstract). J. Urol. 153(Part 2):1995;234a.
61. Torti F.M., Lum B.L., Astom D, et al. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J. Clin. Oncol. 5:1987;125-130.
62. Pansadoro V., Emiliozzi P., de Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacilli Calmette-Guerrin: 18-year experience. Urology. 59:2002;227-231.
63. Hurle R., Losa A., Manzetti A, et al. Intravesical bacillus Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology. 54:1999;258-263.
64. Brake M., Loertzer H., Horsch R, et al. Recurrence and progression of stage T1 grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J. Urol. 163:2000;1697-1701.
65. Zhang G.K., Uke E.T., Sharer W.C, et al. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J. Urol. 155:1996;1907-1909.
66. Soloway M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J. Urol. 167:2002;1573-1583.
67. Gohji K., Nomi M., Okamoto M, et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology. 53:1999;308-313.
68. Meng M.V., Sanda M.G. Comparision of intravesical BCG to radical cystectomy for high grade, T1 transitional call carcinoma using Markov decision tree analysis (Abstract). J. Urol. 153(Part 2):1995;466A.
69. Serretta V., Piazza S., Pavone C, et al. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1G3 transitional cell carcinoma of the bladder. Urology. 47:1996;647-651.
70. Palou J., Rosales A., Chechile G, et al. Long term follow-up of 98 patients with T1G3 transitional cell carcinoma of the bladder treated with BCG (abstract). Br. J. Urol. 80(Suppl 2):1997;36.
71. Vincente J., Laguna M.P., Palou J. The value of conservative treatment in G3T1 bladder tumors. Eur. Urol. Today. 6:1996;14-18.
72. Shahin O., Thalmann G.N., Rentsch C, et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol. 169:2003;96-100.
73. Kwak C., Ku J.H., Park J.Y, et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J. Urol. 171:2004;149-152.
74. Peyromaure M., Guerin F., Amsellem-Ouazana D, et al. Intravesical bacillus Calmette-Guerin therapy for stage T1grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J. Urol. 169:2003;2110-2112.